AXNOTCinactive

AOXING PHARMACEUTICAL COMPANY, INC.

Healthcare·Oncology·Commercial
OncologyPain

AOXING PHARMACEUTICAL COMPANY, INC. (AXN): 3 pipeline candidates. Updated within the last hour.

8.6/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for AOXING PHARMACEUTICAL COMPANY, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

—

Quarterly Burn

$3.0M

Runway

—

Revenue

$5.7M

Pipeline (3 candidates)

DrugPhase
buprenorphine/naloxonePhase 2
tilidineApproved
tilidine / naloxonePhase 2
·CEO: Zhenjiang Yue

Frequently asked questions

How many drug candidates are in AOXING PHARMACEUTICAL COMPANY, INC.'s pipeline?

AOXING PHARMACEUTICAL COMPANY, INC. (AXN) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is AOXING PHARMACEUTICAL COMPANY, INC.'s lead drug candidate?

AOXING PHARMACEUTICAL COMPANY, INC.'s most advanced tracked candidate is buprenorphine/naloxone (Phase 2) for opioid dependence.

Who is the CEO of AOXING PHARMACEUTICAL COMPANY, INC.?

Zhenjiang Yue is the chief executive officer of AOXING PHARMACEUTICAL COMPANY, INC. (AXN).

Get the full picture on AOXING PHARMACEUTICAL COMPANY, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar